Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses

Bibliography

• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-8
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-8
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-9
   PubMed Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5
   PubMed Web of Science ®Google Scholar
• Lund J, Sato A, Akira S, Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003;198:513-20
   PubMed Web of Science ®Google Scholar
• Heil F, Ahmad-Nejad P, Hemmi H, The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003;33:2987-97
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Funami K, Tanabe M, Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003;171:3154-62
   PubMed Web of Science ®Google Scholar
• Ahmad-Nejad P, Hacker H, Rutz M, Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32:1958-68
   PubMed Web of Science ®Google Scholar
• Latz E, Schoenemeyer A, Visintin A, TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190-8
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
   PubMed Web of Science ®Google Scholar
• Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997;278:1612-5
   PubMed Web of Science ®Google Scholar
• Wesche H, Henzel WJ, Shillinglaw W, MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7:837-47
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14
   PubMed Web of Science ®Google Scholar
• Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999;284:1313-8
   PubMed Web of Science ®Google Scholar
• Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004;5:971-4
   PubMed Web of Science ®Google Scholar
• Cornelie S, Hoebeke J, Schacht AM, Direct evidence that Toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J Biol Chem 2004;279:15124-9
   PubMed Web of Science ®Google Scholar
• Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006;7:131-7
   PubMed Web of Science ®Google Scholar
• Copin R, De Baetselier P, Carlier Y, MyD88-dependent activation of B220-CD11b+LY-6C+ dendritic cells during Brucella melitensis infection. J Immunol 2007;178:5182-91
   PubMed Web of Science ®Google Scholar
• Lee KS, Scanga CA, Bachelder EM, TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell Immunol 2007;245:103-10
   PubMed Web of Science ®Google Scholar
• Bafica A, Scanga CA, Feng CG, TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005;202:1715-24
   PubMed Web of Science ®Google Scholar
• Anderson AE, Worku ML, Khamri W, TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. Eur J Immunol 2007;37:1548-61
   PubMedGoogle Scholar
• Hochrein H, Schlatter B, O'Keeffe M, Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci USA 2004;101:11416-21
   PubMed Web of Science ®Google Scholar
• Krug A, French AR, Barchet W, TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004;21:107-19
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007;81:3170-80
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009;119:2388-98
   PubMed Web of Science ®Google Scholar
• Kandimalla ER, Bhagat L, Li Y, Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proc Natl Acad Sci USA 2005;102:6925-30
   PubMed Web of Science ®Google Scholar
• Haas T, Metzger J, Schmitz F, The DNA sugar backbone 2′ deoxyribose determines Toll-like receptor 9 activation. Immunity 2008;28:315-23
   PubMed Web of Science ®Google Scholar
• Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249-58
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9
   PubMed Web of Science ®Google Scholar
• Bauer S, Kirschning CJ, Hacker H, Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-42
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95
   PubMed Web of Science ®Google Scholar
• Pedersen G, Andresen L, Matthiessen MW, Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol 2005;141:298-306
   PubMed Web of Science ®Google Scholar
• Lebre MC, van der Aar AM, van Baarsen L, Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007;127:331-41
   PubMed Web of Science ®Google Scholar
• Platz J, Beisswenger C, Dalpke A, Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004;173:1219-23
   PubMed Web of Science ®Google Scholar
• Brandenburg B, Zhuang X. Virus trafficking – learning from single-virus tracking. Nat Rev Microbiol 2007;5:197-208
   PubMed Web of Science ®Google Scholar
• Tabeta K, Hoebe K, Janssen EM, The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006;7:156-64
   PubMed Web of Science ®Google Scholar
• Brinkmann MM, Spooner E, Hoebe K, The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 2007;177:265-75
   PubMed Web of Science ®Google Scholar
• Latz E, Verma A, Visintin A, Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007;8:772-9
   PubMed Web of Science ®Google Scholar
• O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7:353-64
   PubMed Web of Science ®Google Scholar
• Kawagoe T, Sato S, Jung A, Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J Exp Med 2007;204:1013-24
   PubMed Web of Science ®Google Scholar
• Deng L, Wang C, Spencer E, Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000;103:351-61
   PubMed Web of Science ®Google Scholar
• Sato S, Sanjo H, Takeda K, Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6:1087-95
   PubMed Web of Science ®Google Scholar
• Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219-26
   PubMed Web of Science ®Google Scholar
• Kawai T, Sato S, Ishii KJ, Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004;5:1061-8
   PubMed Web of Science ®Google Scholar
• Izaguirre A, Barnes BJ, Amrute S, Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003;74:1125-38
   PubMed Web of Science ®Google Scholar
• Honda K, Ohba Y, Yanai H, Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005;434:1035-40
   PubMed Web of Science ®Google Scholar
• Shinohara ML, Lu L, Bu J, Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 2006;7:498-506
   PubMed Web of Science ®Google Scholar
• Abou Fakher FH, Rachinel N, Klimczak M, TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions. J Immunol 2009;182:1386-96
   PubMedGoogle Scholar
• Samuelsson C, Hausmann J, Lauterbach H, Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008;118:1776-84
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeda K, Akira S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003;170:3059-64
   PubMed Web of Science ®Google Scholar
• Lipford GB, Sparwasser T, Zimmermann S, CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000;165:1228-35
   PubMed Web of Science ®Google Scholar
• Horkheimer I, Quigley M, Zhu J, Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. Blood 2009;113:5330-9
   PubMedGoogle Scholar
• Vaidya SA, Cheng G. Toll-like receptors and innate antiviral responses. Curr Opin Immunol 2003;15:402-7
   PubMed Web of Science ®Google Scholar
• Garcia-Sastre A, Biron CA. Type 1 interferons and the virus–host relationship: a lesson in detente. Science 2006;312:879-82
   PubMed Web of Science ®Google Scholar
• Hoebe K, Janssen EM, Kim SO, Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 2003;4:1223-9
   PubMed Web of Science ®Google Scholar
• Le Bon A, Etchart N, Rossmann C, Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-15
   PubMed Web of Science ®Google Scholar
• Cousens LP, Peterson R, Hsu S, Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J Exp Med 1999;189:1315-28
   PubMed Web of Science ®Google Scholar
• Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521-30
   PubMed Web of Science ®Google Scholar
• Lucas M, Schachterle W, Oberle K, Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007;26:503-17
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5:112-24
   PubMed Web of Science ®Google Scholar
• Liu N, Ohnishi N, Ni L, CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 2003;4:687-93
   PubMed Web of Science ®Google Scholar
• He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004;173:4479-91
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005;438:364-8
   PubMed Web of Science ®Google Scholar
• Gavin AL, Hoebe K, Duong B, Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 2006;314:1936-8
   PubMed Web of Science ®Google Scholar
• Chu RS, Targoni OS, Krieg AM, CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997;186:1623-31
   PubMed Web of Science ®Google Scholar
• Roman M, Martin-Orozco E, Goodman JS, Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-54
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 2006;311:155-78
   PubMed Web of Science ®Google Scholar
• Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009;61:195-204
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J Clin Immunol 2004;24:693-701
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22:3136-43
   PubMed Web of Science ®Google Scholar
• Klinman DM. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. Expert Rev Vaccines 2006;5:365-9
   PubMed Web of Science ®Google Scholar
• Kline JN, Waldschmidt TJ, Businga TR, Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998;160:2555-9
   PubMed Web of Science ®Google Scholar
• Simons FE, Shikishima Y, Van Nest G, Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004;113:1144-51
   PubMed Web of Science ®Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG, Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-55
   PubMed Web of Science ®Google Scholar
• Campbell JD, Cho Y, Foster ML, CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans. J Clin Invest 2009;119:2564-76
   PubMedGoogle Scholar
• Krieg AM, Efler SM, Wittpoth M, Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004;27:460-71
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004;5:508-15
   PubMed Web of Science ®Google Scholar
• Speiser DE, Lienard D, Rufer N, Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-46
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-36
   PubMed Web of Science ®Google Scholar
• Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007;220:251-69
   PubMed Web of Science ®Google Scholar
• Yasutomo K, Horiuchi T, Kagami S, Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001;28:313-4
   PubMed Web of Science ®Google Scholar
• Shin HD, Park BL, Cheong HS, DNase II polymorphisms associated with risk of renal disorder among systemic lupus erythematosus patients. J Hum Genet 2005;50:107-11
   PubMed Web of Science ®Google Scholar
• Lee-Kirsch MA, Gong M, Chowdhury D, Mutations in the gene encoding the 3′–5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007;39:1065-7
   PubMed Web of Science ®Google Scholar
• Means TK, Latz E, Hayashi F, Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7
   PubMed Web of Science ®Google Scholar
• Ehlers M, Fukuyama H, McGaha TL, TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203:553-61
   PubMed Web of Science ®Google Scholar
• Ho PP, Fontoura P, Ruiz PJ, An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 2003;171:4920-6
   PubMed Web of Science ®Google Scholar
• Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheum 2005;52:651-8
   PubMed Web of Science ®Google Scholar
• Huang X, Yang Y. Innate immune recognition of viruses and viral vectors. Hum Gene Ther 2009;20:293-301
   PubMed Web of Science ®Google Scholar
• Basner-Tschakarjan E, Gaffal E, O'Keeffe M, Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J Gene Med 2006;8:1300-6
   PubMedGoogle Scholar
• Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J Virol 2007;81:4145-57
   PubMedGoogle Scholar
• Dustin ML. Multiscale analysis of T cell activation: correlating in vitro and in vivo analysis of the immunological synapse. Curr Top Microbiol Immunol 2009;334:47-70
   PubMedGoogle Scholar
• Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006;24:93-103
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Coban C, Kato H, A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006;7:40-8
   PubMed Web of Science ®Google Scholar
• Kawane K, Ohtani M, Miwa K, Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006;443:998-1002
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK, DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448:501-5
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Kawagoe T, Koyama S, TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008;451:725-9
   PubMed Web of Science ®Google Scholar